What is Pharmacovigilance?

It covers scientific studies with regard to the detection, evaluation, identification, and prevention of adverse (side) effects and other problems related to human medicinal products. Pharmacovigilance can be defined as “collection of clinical data on the safety of drugs in daily clinical practice, monitoring of problems encountered in drug administration, and detection, identification, investigation, recording, announcing of responsible causes and taking necessary precautions”.

Pharmacovigilance Studies in our Country:

Turkish Pharmaceutical Adverse Effects Monitoring and Evaluation Center (TADMER) was founded in 1985 and was accepted as the 27th member of the WHO Collaborating Centre for International Drug Monitoring in 1987. The name of the center, which was the Turkish Pharmaceutical Adverse Effects Monitoring and Evaluation Center (TADMER), has changed to the Farmakovijilans Center of Turkey (TÜFAM). “The Regulation on Monitoring and Evaluating the Safety of Human Medical Products” was first published on 22.03.2005 and later amended with the “Regulation on the Safety of Drugs” published in the Official Gazette dated 15/4/2014 and numbered 28973, which was prepared in parallel with directive 2010/84/EC of the current legislation of the European Union on medicines.

Adverse Reaction Notification Form:

Please fill out the TÜFAM notification form for the notification of side effects/adverse reactions, and send it to the

Select File